Roivant Sciences
ROIV Nasdaq· Biotechnology
Last close · Oct 23, 2026
$36.49
KIRA · Stoqly’s AI analyst, in plain words
- Roivant Sciences had $8.3M of revenue in fiscal 2025, down 71.6% on the year before. Over five years, revenue changed −19.0% a year on average.
- Its operating margin was −6,235.7%, down 2,782.4 pts: of every 100 in sales, about −6,236 is left after running the business.
- Roivant Sciences lost $300M in fiscal 2025.
- Free cash flow was −$759M in fiscal 2025, −9,183.5% of revenue.
- Roivant Sciences returned $0.0M to shareholders in fiscal 2025. The diluted share count fell 4.4%.
- Roivant Sciences has $4.3B more cash than debt.
Market cap
$26.3B
P/E
—
Revenue
$8.3M
Net income
−$300M
Free cash flow
−$759M
Operating margin
−6,235.7%
Roivant Sciences in 30 seconds · fiscal 2025
Are sales growing?
−71.6%
No. Sales fell 71.6% last year.
Does it make a profit?
−3,629.2%
No. It lost money last year.
Does profit turn into cash?
−9,183.5%
No. It spent more cash than it brought in.
How healthy are the accounts?
1 / 8
Weak. It passes 1 of 8 health tests.
What Roivant Sciences does
No business description yet.
- Fiscal year ends
- March 31, 2026
- Latest annual report
- 10-K · May 20, 2026
- Legal name
- ROIVANT SCIENCES LTD.
- CIK
- 0001635088
Roivant Sciences · ROIV
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $55.3M | $31.5M | $32.7M | $29.1M | $8.3M |
| Revenue growth | 132.3% | −43.0% | 3.8% | −11.2% | −71.6% |
| Operating margin | −2,444.8% | −2,875.9% | 13,746.9% | −3,453.3% | −6,235.7% |
| Net income | −$845M | −$1.0B | $4.3B | −$172M | −$300M |
| Net margin | −1,528.9% | −3,200.2% | 13,294.2% | −592.0% | −3,629.2% |
| Diluted EPS | −$1.26 | −$1.42 | $5.23 | −$0.24 | −$0.54 |
| Cash | |||||
| Cash from operations | −$678M | −$843M | −$765M | −$840M | −$750M |
| Capital expenditure | $17.4M | $12.7M | $1.4M | $4.6M | $8.2M |
| Free cash flow | −$695M | −$856M | −$767M | −$844M | −$759M |
| FCF margin | −1,257.4% | −2,715.1% | −2,343.6% | −2,905.2% | −9,183.5% |
| Dividends paid | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Share buybacks | $0.0M | $0.0M | $0.0M | $1.3B | $0.0M |
| Share count change | 6.3% | 6.4% | 16.6% | −12.7% | −4.4% |
| Debt and strength | |||||
| Cash and short-term investments | $2.1B | $1.7B | $6.5B | $4.9B | $4.3B |
| Debt incl. finance leases | $210M | $381M | $431M | $0.0M | $0.0M |
| Shareholders' equity | $1.7B | $1.2B | $6.0B | $4.7B | $4.5B |
| Net debt / EBITDA | — | — | −1.3x | — | — |
| Current ratio | 11.6x | 6.6x | 25.2x | 33.5x | 18.4x |
| Interest coverage | −192.0x | −32.4x | 129.3x | −168.3x | — |
| Returns and quality | |||||
| Return on capital | — | −286.2% | — | — | −62.6% |
| Return on equity | −48.9% | −71.7% | 122.1% | −3.2% | −6.5% |
| Piotroski F-score | — | 1 | 5 | 3 | 1 |
| Altman Z'' | 2.1 | −1.4 | 19.1 | 26.5 | 18.1 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$885M
12 insiders
Of sales under plans
18%
$155M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Roivant Sciences · ROIV
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Similar companies
Each company’s latest fiscal year. Fiscal years end in different months, so periods don’t line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score |
|---|---|---|---|---|---|---|---|
| Roivant Sciences ROIV | $26.3B | −71.6% | −6,235.7% | −9,183.5% | −62.6% | — | 1 |
| Cytokinetics CYTK | — | 376.6% | −695.4% | −607.5% | — | — | — |
| Ligand Pharmaceuticals LGND | $6.6B | 60.4% | 15.3% | 18.2% | 4.9% | 32.3x | 5 |
| Krystal Biotech KRYS | $9.6B | 33.9% | 41.5% | 48.6% | 43.6% | 39.0x | 5 |
| ADMA Biologics ADMA | $2.5B | 19.6% | 37.5% | 5.5% | 39.5% | 15.3x | 5 |
KIRA
At $36.49 a share, the company is worth $26.3B.
Roivant Sciences grew sales faster than 0 of its 4 similar companies.
Source: SEC EDGAR XBRL filings (CIK 0001635088). Data updated October 11, 2026. For information only — not investment advice. Check the original filings before relying on any figure.